While an effective dose range for CBD in patients with SCN8A mutations has not yet been established, in a long-term open label trial in patients with DS and Lennox-Gastaut syndrome (GWPCARES, NCT02224573), CBD doses from 2.5 to 20 mg/kg/d were administered. This evidence concerns the gene SCN8A and Dravet syndrome.